Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis

Stefano Molica, Diana Giannarelli, Rosanna Mirabelli, Luciano Levato, Neil E. Kay, Tait D. Shanafelt

Blood (2018) 131 (3): 365–368.

https://doi.org/10.1182/blood-2017-09-806034

Published: 2018

Includes: Supplemental data

Journal Articles

A Simple Score, Based on Geriatric Assessment, Predicts Survival in Elderly Newly Diagnosed Chronic Lymphocytic Leukemia Patients

Stefano Molica, MD, Diana Giannarelli, PhD, Luciano Levato, MD, Rosanna Mirabelli, MD, Domenico Levato, MD, Mirella Lentini, PhD, Eugenio Piro, MD, Daniela Zappalà, PhD

Blood (2016) 128 (22): 2036.

https://doi.org/10.1182/blood.V128.22.2036.2036

Published: 2016

Journal Articles

Is the International Prognostic INDEX for CLL (CLL-IPI) Useful to Predict Time to First Treatment of Patients with EARLY Disease? Results of a Prospective Multicenter Analysis

Stefano Molica, MD, Diana Giannarelli, MD, Luciano Levato, MD, Rosanna Mirabelli, MD, Massimo Gentile, MD, Fortunato Morabito, MD

Blood (2015) 126 (23): 498.

https://doi.org/10.1182/blood.V126.23.498.498

Published: 2015

Journal Articles

VITAMIN D Insufficiency Affects Time to FIRST TREATMENT (TFT) In EARLY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Stefano Molica, MD, Giovanna Digiesi, MD, Anna Antenucci, MD, Luciano Levato, Rosanna Mirabelli, MD, Massimo Gentile, MD, Diana Giannarelli, MD, Isabella Sperduti, PhD, Fortunato Morabito, MD, Laura Conte, MD

Blood (2011) 118 (21): 4601.

https://doi.org/10.1182/blood.V118.21.4601.4601

Published: 2011

Journal Articles

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

Blood (2010) 116 (21): 2471.

https://doi.org/10.1182/blood.V116.21.2471.2471

Published: 2010

Journal Articles

Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Stefano Molica, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Rosanna Mirabelli, MD, Giovanna Digiesi, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Fortunato Morabito, Manlio Ferrarini, MD

Blood (2008) 112 (11): 4187.

https://doi.org/10.1182/blood.V112.11.4187.4187

Published: 2008

Journal Articles

Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Stefano Molica, MD, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Giovanna Digiesi, MD, Rosanna Mirabelli, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Manlio Ferrarini, MD

Blood (2008) 112 (11): 4158.

https://doi.org/10.1182/blood.V112.11.4158.4158

Published: 2008

Journal Articles

Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Stefano Molica, MD, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Giovanna Digiesi, MD, Rosanna Mirabelli, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Manlio Ferrarini, MD

Blood (2007) 110 (11): 3093.

https://doi.org/10.1182/blood.V110.11.3093.3093

Published: 2007

Journal Articles

Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Stefano Molica, MD, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Giovanna Digiesi, MD, Rosanna Mirabelli, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Manlio Ferrarini, MD

Blood (2006) 108 (11): 2786.

https://doi.org/10.1182/blood.V108.11.2786.2786

Published: 2006

Journal Articles

Intense Reversal of Bone Marrow Angiogenesis after Consolidation Therapy with Alemtuzumab in Advanced Chronic Lymphocytic Leukemia.

Stefano Molica, MD, Marco Montillo, MD, Domenico Ribatti, MD, Rosanna Mirabelli, MD, Alessandra Tedeschi, MD, Francesca Ricci, MD, Silvio Veronese, MD, Angelo Vacca, MD, Enrica Morra, MD

Blood (2006) 108 (11): 4985.

https://doi.org/10.1182/blood.V108.11.4985.4985

Published: 2006

Journal Articles

Characteristics and Outcome of B-Cell Chronic Lymphocytic Leukemia in HCV-Positive Patients.

Stefano Molica, MD, Rosanna Mirabelli, MD, Demetrio Misuraca, MD, Caterina Battaglia, MD

Blood (2005) 106 (11): 4986.

https://doi.org/10.1182/blood.V106.11.4986.4986

Published: 2005

Journal Articles

Serum Insulinlike Growth Factor Is Not Elevated in Patients with Early B-Cell Chronic Lymphocytic Leukemia but Is Still a Prognostic Factor for Disease-Progression.

Stefano Molica, MD, Gaetano Vitelli, MD, Rosanna Mirabelli, MD, Giovanna Digiesu, MD, Diana Giannarelli, MD, Antonella Iorfida, PhD

Blood (2004) 104 (11): 4786.

https://doi.org/10.1182/blood.V104.11.4786.4786

Published: 2004

NARROW

Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis

A Simple Score, Based on Geriatric Assessment, Predicts Survival in Elderly Newly Diagnosed Chronic Lymphocytic Leukemia Patients

Is the International Prognostic INDEX for CLL (CLL-IPI) Useful to Predict Time to First Treatment of Patients with EARLY Disease? Results of a Prospective Multicenter Analysis

VITAMIN D Insufficiency Affects Time to FIRST TREATMENT (TFT) In EARLY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Intense Reversal of Bone Marrow Angiogenesis after Consolidation Therapy with Alemtuzumab in Advanced Chronic Lymphocytic Leukemia.

Characteristics and Outcome of B-Cell Chronic Lymphocytic Leukemia in HCV-Positive Patients.

Serum Insulinlike Growth Factor Is Not Elevated in Patients with Early B-Cell Chronic Lymphocytic Leukemia but Is Still a Prognostic Factor for Disease-Progression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only